The 2010 Affordable Care Act established the Medicare Annual Wellness Visit (AWV) as an opportunity for Medicare beneficiaries to receive preventive and assessment services during visits with their primary care providers (PCPs). Detection of cognitive impairment is among required AWV services, yet no specific tools are mandated and no data are available regarding tools used for this purpose. This webinar explains these and related issues being addressed by a Workgroup convened by GSA and supported by Lilly on Cognitive Impairment Detection and Earlier Diagnosis, charged with summarizing available evidence-based cognitive impairment detection tools for use by PCPs, and recommending how more uniform detection can be adopted nationally via the AWV, leading to earlier and improved diagnosis and links with post-diagnosis support services to benefit people with dementia and their families. Presentations from a multidisciplinary panel of Workgroup members will include: (1) an overview of the Workgroup’s charge and progress; (2) clinical guidelines for the AWV and efforts by the Centers for Medicare and Medicaid Services to promote cognitive impairment detection by PCPs during the AWV; (3) connections between earlier cognitive impairment detection, earlier dementia diagnosis, and improved access to post-diagnostic services, particularly increasingly available evidence-based non-pharmacologic interventions and care practices for people with dementia and their families.